MAM
Elan Group appoints Shah Rukh Khan as brand ambassador
MUMBAI : In a landmark move set to redefine India’s luxury real estate sector, Gurugram based Elan Group has announced the appointment of Indian cinema icon Shah Rukh Khan (SRK) as its brand ambassador.
Renowned for its architectural excellence and innovation, Elan Group is a dominant force in ultra-luxury real estate. With this collaboration, the brand is poised to reach new heights, pushing the boundaries of opulence and grandeur.
Under the leadership of Rakesh Kapoor, Ravish Kapoor, and Akash Kapoor, Elan Group has developed 15 iconic projects across residential, commercial, and mixed-use spaces. The brand is not only transforming skylines but also setting new benchmarks in design, exclusivity, and prestige.
SRK, celebrated for his global influence and trailblazing career, shares Elan’s vision of excellence and ambition. His partnership with the company is more than just an endorsement it represents a shared commitment to innovation, perfection, and success.
Expressing his excitement, SRK stated, “Greatness belongs to those who dare to push limits. Elan Group embodies that fearless spirit, and I’m thrilled to be part of this journey.”
Elan Group director, Akash added, “We are honoured to welcome SRK to the Elan family. At Elan, we don’t just create projects we build icons. His unmatched presence and relentless pursuit of perfection mirror our philosophy and vision.”
With this alliance, Elan Group and SRK are set to shape the future of luxury living in India.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
